Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Diabetes Care

• Publication date

  2016-10-17

• Fields of study

  Medicine

• Identifiers
  DOI 10.2337/dc16-0621PMID 27797925
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of the ALTITUDE trial

  2016cited by this paper
• Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis.

  2015influential reference
• Urinary Albumin Secretion in Type 2 Diabetes Patients (T2DM) With Albuminuria Treated With Sitagliptin as Add-on Therapy to Metformin: A Real World Data Study

  2014cited by this paper
• Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial

  2014cited by this paper
• Microalbuminuria as a Risk Predictor in Diabetes: The Continuing Saga

  2014cited by this paper
• The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential.

  2014cited by this paper
• Diabetic Kidney Disease: A Report From an ADA Consensus Conference

  2014influential reference
• Mortality and morbidity in relation to changes in albuminuria, glucose status and systolic blood pressure: an analysis of the ONTARGET and TRANSCEND studies

  2014cited by this paper
• Sitagliptin improves albuminuria in patients with type 2 diabetes mellitus

  2013cited by this paper
• Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

  2013influential reference
• Linagliptin Lowers Albuminuria on Top of Recommended Standard Treatment in Patients With Type 2 Diabetes and Renal Dysfunction

  2013cited by this paper
• Association Between Urinary Albumin Excretion and Low-density Lipoprotein Heterogeneity Following Treatment of Type 2 Diabetes Patients with the Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin: A Pilot Study

  2013cited by this paper
• Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)‐TIMI 53 trial

  2013cited by this paper
• Protective Effects of GLP-1 on Glomerular Endothelium and Its Inhibition by PKCβ Activation in Diabetes

  2012cited by this paper
• Proteinuria should be used as a surrogate in CKD

  2012cited by this paper
• Dipeptidyl Peptidase IV Inhibitor Attenuates Kidney Injury in Streptozotocin-Induced Diabetic Rats

  2012cited by this paper
• GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases.

  2012cited by this paper
• DPP-4 Inhibition on Top of Angiotensin Receptor Blockade Offers a New Therapeutic Approach for Diabetic Nephropathy

  2012cited by this paper
• Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study.

  2012cited by this paper
• Sitagliptin reduces albuminuria in patients with type 2 diabetes.

  2011cited by this paper
• Initial Angiotensin Receptor Blockade–Induced Decrease in Albuminuria Is Associated With Long-Term Renal Outcome in Type 2 Diabetic Patients With Microalbuminuria

  2011cited by this paper
• The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study.

  2011cited by this paper
• Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes

  2011cited by this paper
• Diabetic Nephropathy Amelioration by a Low-Dose Sitagliptin in an Animal Model of Type 2 Diabetes (Zucker Diabetic Fatty Rat)

  2011cited by this paper
• Influence of albuminuria on cardiovascular risk in patients with stable coronary artery disease. Circulation 116: 2687-2693, 2007.

  2008cited by this paper
• Reduction in Microalbuminuria as an Integrated Indicator for Renal and Cardiovascular Risk Reduction in Patients With Type 2 Diabetes

  2007cited by this paper
• Biology of incretins: GLP-1 and GIP.

  2007cited by this paper
• Influence of Albuminuria on Cardiovascular Risk in Patients With Stable Coronary Artery Disease

  2007cited by this paper
• Risk Factors for Renal Dysfunction in Type 2 Diabetes

  2006cited by this paper
• Microalbuminuria as an early marker for cardiovascular disease.

  2006cited by this paper
• The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension.

  2005cited by this paper
• Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.

  2004cited by this paper
• Diabetic nephropathy: Linking histology, cell biology, and genetics.

  2004cited by this paper
• National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification

  2003cited by this paper
• Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).

  2003cited by this paper
• Albuminuria and Risk of Cardiovascular Events , Death , and Heart Failure in Diabetic and Nondiabetic Individuals

  2002cited by this paper
• Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals.

  2001cited by this paper
• A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation

  1999cited by this paper

• Effect of SGLT2 inhibitors versus DPP4 inhibitors on major adverse kidney events in diabetic people with varied kidney function decline

  2026cites this paper
• Dual blockade of DPP-4 and CXCL12/CXCR4 axes synergistically protects podocytes in lupus nephritis

  2026cites this paper
• Targeting programmed cell death pathways: emerging therapeutic strategies for diabetic kidney disease

  2025cites this paper
• Treatment of type 2 diabetes mellitus - a current view of the different drug classes and strategies for their use

  2025cites this paper
• Comparative analysis on renal and cardiovascular outcomes of antidiabetic treatment in chronic kidney disease patients—A systematic review and network meta‐analysis

  2025cites this paper
• Discovery of XRF-1021, a 2,4-disubstituted-5-fluoropyrimidine derivative as a homeodomain-interacting protein kinase 2 inhibitor for the treatment of chronic kidney disease.

  2025cites this paper
• Research Progress and Clinical Application of Drugs for Diabetic Kidney Disease

  2025cites this paper
• Choosing oral antihyperglycaemic drugs in people living with Type 2 diabetes and severe chronic kidney disease

  2025cites this paper
• Dipeptidyl peptidase 4 (DPP-4) inhibitors for people with chronic kidney disease and diabetes.

  2025cites this paper
• Use of dipeptidyl peptidase‐4 inhibitors is associated with lower risk of severe renal outcomes in pre‐dialysis patients with Type 2 diabetes

  2025cites this paper
• Effectiveness of Insulin Versus Oral Agents in Patients with Uncontrolled Type 2 Diabetes Mellitus: A Retrospective Comparative Study

  2025cites this paper
• Chronic Kidney Disease in Patients With Heart Failure With a Preserved Ejection Fraction

  2025cites this paper
• Mesangial Cells in Diabetic Kidney Disease: From Mechanisms to Therapeutic Implications

  2025cites this paper
• Targeting NF-κB in diabetic nephropathy: exploring the therapeutic potential of phytoconstituents

  2025cites this paper
• Use of SGLT2 Inhibitors vs GLP-1 RAs and Anemia in Patients With Diabetes and CKD

  2024cites this paper
• Effect of DPP-4i inhibitors on renal function in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials

  2024cites this paper
• Factors Involved in the Development of Diabetic Kidney Disease in Patients With Slowly Progressive Type 1 Diabetes Mellitus: A Retrospective Cohort Study

  2024cites this paper
• Comparative effects of sodium–glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors on kidney function decline in Japanese individuals with type 2 diabetes

  2024cites this paper
• Emerging role of antidiabetic drugs in cardiorenal protection

  2024cites this paper
• Safety and Efficiency of Dipeptidyl Peptidase IV Inhibitors in Patients with Diabetic Kidney Disease: A Systematic Review and Meta-Analysis

  2024cites this paper
• To target cellular senescence in diabetic kidney disease: the known and the unknown

  2024cites this paper
• Incretin-based therapy: a new horizon in diabetes management

  2024cites this paper
• Advances in the Pharmacological Management of Diabetic Nephropathy: A 2022 International Update

  2023cites this paper
• Long-Term, Real-World Kidney Outcomes with SGLT2i versus DPP4i in Type 2 Diabetes without Cardiovascular or Kidney Disease

  2023cites this paper
• Effektive antidiabetische Therapie zur Vorbeugung einer diabetischen Nephropathie

  2023cites this paper
• Incretins and microvascular complications of diabetes: neuropathy, nephropathy, retinopathy and microangiopathy

  2023cites this paper
• Effects of Dipeptidyl Peptidase-4 Inhibitor and Angiotensin Converting Enzyme Inhibitor on Experimental Diabetic Kidney Disease.

  2023cites this paper
• SAFETY PROFILE OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS

  2023cites this paper
• Comparative Efficacy of Novel Antidiabetic Drugs on Albuminuria Outcomes in Type 2 Diabetes: A Systematic Review

  2023influential citation
• Drug Therapies for Diabetes

  2023cites this paper
• Cardiovascular and Renal Outcomes with SGLT-2 inhibitors and DPP-4 inhibitors Combination Therapy: A Meta-analysis of Randomized Cardiovascular Outcome Trials.

  2023cites this paper
• Impact of chronic GLP-1 RA and SGLT-2I therapy on in-hospital outcome of diabetic patients with acute myocardial infarction

  2023cites this paper
• Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal evaluations in the CORDIALLY® study

  2022cites this paper
• Traditional Chinese medicine for the treatment of diabetic kidney disease: A study-level pooled analysis of 44 randomized controlled trials

  2022cites this paper
• Diabetic Kidney Care Redefined with a New Way into Remission.

  2022cites this paper
• NLRP3-mediated pyroptosis in diabetic nephropathy

  2022cites this paper
• Renal outcomes with sodium-glucose cotransporters 2 inhibitors

  2022cites this paper
• Enterorenal crosstalks in diabetic nephropathy and novel therapeutics targeting the gut microbiota

  2022cites this paper
• Diabetic Proteinuria Revisited: Updated Physiologic Perspectives

  2022cites this paper
• Repurposing drugs for highly prevalent diseases: pentoxifylline, an old drug and a new opportunity for diabetic kidney disease

  2022cites this paper
• Targeted drug delivery strategy: a bridge to the therapy of diabetic kidney disease

  2022cites this paper
• Pharmacotherapy of type 2 diabetes: An update and future directions.

  2022cites this paper
• The Effects of Dipeptidyl Peptidase 4 Inhibitors on Renal Function in Patients with Type 2 Diabetes Mellitus

  2022cites this paper
• Patients’ Preference Between DPP4i and SGLT2i for Type 2 Diabetes Treatment: A Cross-Sectional Evaluation

  2022cites this paper
• Clinical practice guidelines for management of hyperglycaemia in adults with diabetic kidney disease

  2022cites this paper
• Effect of Anagliptin versus Sitagliptin on Renal Function: Subanalyzes from the REASON Trial

  2022cites this paper
• New trends in the approach to the treatment of type 2 diabetes - observations and benefits in the outpatient practice of a diabetologist

  2022cites this paper
• Dipeptidyl Peptidase-4 (DPP4) Inhibitors

  2022cites this paper
• Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes

  2022cites this paper
• Recent advances in the pharmacotherapeutic management of diabetic kidney disease

  2022cites this paper
• Extra-Glycemic Effects of Anti-Diabetic Medications: Two Birds with One Stone?

  2022cites this paper
• Treatment of diabetes mellitus has borne much fruit in the prevention of cardiovascular disease

  2022cites this paper
• Glomerular filtration rate as a kidney outcome of diabetic kidney disease: a focus on new antidiabetic drugs

  2022cites this paper
• Postprandial renal haemodynamic effects of the dipeptidyl peptidase‐4 inhibitor linagliptin versus the sulphonylurea glimepiride in adults with type 2 diabetes (RENALIS): A predefined substudy of a randomized, double‐blind trial

  2021cites this paper
• CARDIOVASCULAR EFFECTS OF NON-INSULIN GLUCOSE-LOWERING AGENTS: A COMPREHENSIVE REVIEW OF TRIAL EVIDENCE AND POTENTIAL CARDIOPROTECTIVE MECHANISMS.

  2021cites this paper
• Cardiovascular Outcomes Trials of Incretin-Based Therapies

  2021cites this paper
• Xiao Zheng San Jie Granules in the Treatment of Qi Deficiency and Blood Stasis Syndrome in Patients With Diabetic Kidney Disease Stage IV: Protocol for a Randomised, Double-blind, Placebo-controlled, Multi-centre Trial

  2021cites this paper
• Advances in Clinical Research in Chronic Kidney Disease

  2021cites this paper
• Consensus Recommendations by the Asian Pacific Society of Cardiology: Optimising Cardiovascular Outcomes in Patients with Type 2 Diabetes

  2021cites this paper
• Urinary exosomal microRNA profiling in type 2 diabetes patients taking dipeptidyl peptidase-4 inhibitor compared with sulfonylurea

  2021cites this paper
• Recent therapeutic targets in diabetic nephropathy

  2021cites this paper
• Antidiabetika zur Progressionshemmung der Nephropathie

  2021cites this paper
• How to Assess Diabetic Kidney Disease Progression? From Albuminuria to GFR

  2021cites this paper
• SGLT2 Inhibitors and Other Novel Therapeutics in the Management of Diabetic Kidney Disease.

  2021cites this paper
• The Risk Threshold for Hemoglobin A1c Associated With Albuminuria: A Population-Based Study in China

  2021cites this paper
• Recent advances in new-onset diabetes mellitus after kidney transplantation

  2021cites this paper
• Renal Outcomes with Anti-Diabetic Medications and Clinical Implications in Type 2 Diabetes

  2021cites this paper
• Decreased mortality after long term treatment with DPP-4 inhibitors: A retrospective study of US veterans with type 2 diabetes.

  2021cites this paper
• Association of Renal and Cardiovascular Safety With DPP‐4 Inhibitors vs. Sulfonylureas in Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease

  2021cites this paper
• Diabetic kidney disease: update on clinical management and non-glycaemic effects of newer medications for type 2 diabetes

  2021cites this paper
• A New Clinical Utility for Tubular Markers to Identify Kidney Responders to Saxagliptin Treatment in Adults With Diabetic Nephropathy.

  2021cites this paper
• Renoprotective Effects of DPP-4 Inhibitors

  2021cites this paper
• Lower risk of death and cardiovascular events in patients with diabetes initiating glucagon‐like peptide‐1 receptor agonists or sodium‐glucose cotransporter‐2 inhibitors: A real‐world study in two Italian cohorts

  2021cites this paper
• Heterogeneity in renal end points of cardiovascular outcomes trials in Type 2 diabetes.

  2021cites this paper
• Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial

  2021cites this paper
• Comparative Renal Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter 2 Inhibitors on Individual Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis

  2021influential citation
• Incretin-based drugs and the kidney in type 2 diabetes: choosing between DPP-4 inhibitors and GLP-1 receptor agonists.

  2021cites this paper
• Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial

  2021cites this paper
• Expert Consensus on Telemedicine Management of Diabetes (2020 Edition)

  2021cites this paper
• Inhibition of Podocytes DPP4 Activity Is a Potential Mechanism of Lobeliae Chinensis Herba in Treating Diabetic Kidney Disease

  2021cites this paper
• Effects of DPP4 Inhibitors on Renal Outcomes in Diabetes Mellitus: A Systematic Review and Meta-Analysis

  2021cites this paper
• Changing the Concept: From the Traditional Glucose-centric to the New Cardiorenal-metabolic Approach for the Treatment of Type 2 Diabetes.

  2021influential citation
• Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape

  2021cites this paper
• Utilisation and expenditure on glucose-lowering drugs used for the treatment of type 2 diabetes mellitus in Ireland, a repeated cross-sectional study

  2021cites this paper
• Dipeptidyl Peptidase-4 Inhibitors and Diabetic Kidney Disease: A Narrative Review

  2021cites this paper
• Renal outcomes associated with glucose-lowering agents: Systematic review and meta-analysis of randomized outcome trials.

  2021cites this paper
• Assessing reproducibility and utility of clustering of patients with type 2 diabetes and established CV disease (SAVOR -TIMI 53 trial)

  2021cites this paper
• Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis.

  2021cites this paper
• Dipeptidyl Peptidase-4 Inhibitors

  2021cites this paper
• Chronic kidney disease in patients with diabetes mellitus

  2021cites this paper
• Incretins in the Therapy of Diabetic Kidney Disease

  2021cites this paper
• Novel Therapies for Kidney Disease in People with Diabetes.

  2021cites this paper
• Kidney function assessment and endpoint ascertainment in clinical trials.

  2021cites this paper
• Lower Risk of Death and Cardiovascular Events in Unselected Type 2 Diabetes Patients Initiated on GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Two Large Italian Cohorts

  2020cites this paper
• 2020 Consensus of Taiwan Society of Cardiology on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases.

  2020cites this paper
• Diabetic Kidney Disease

  2020cites this paper
• Diabetic Kidney Disease in Childhood and Adolescence: Conventional and Novel Renoprotective Strategies

  2020cites this paper
• Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the LEADER randomized trial

  2020cites this paper
• Pleiotropic effects of antidiabetic agents on renal and cardiovascular outcomes: a meta-analysis of randomized controlled trials

  2020cites this paper
• Brief Review of Newer Antiglycemic Agents as Options in the Treatment of Diabetic Kidney Disease

  2020cites this paper